Dodge & Cox Sells 346,600 Shares of Fresenius Medical Care AG & Co. KGaA $FMS

Dodge & Cox cut its holdings in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 8.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,826,910 shares of the company’s stock after selling 346,600 shares during the quarter. Dodge & Cox’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $109,335,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. TD Waterhouse Canada Inc. bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the 2nd quarter valued at $36,000. Brooklyn Investment Group grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 424.5% during the first quarter. Brooklyn Investment Group now owns 1,285 shares of the company’s stock worth $32,000 after purchasing an additional 1,040 shares during the period. Atlantic Union Bankshares Corp bought a new stake in Fresenius Medical Care AG & Co. KGaA in the second quarter valued at about $43,000. Hantz Financial Services Inc. increased its holdings in Fresenius Medical Care AG & Co. KGaA by 568.5% in the second quarter. Hantz Financial Services Inc. now owns 2,079 shares of the company’s stock valued at $59,000 after purchasing an additional 1,768 shares during the last quarter. Finally, Huntington National Bank lifted its stake in Fresenius Medical Care AG & Co. KGaA by 219.5% in the second quarter. Huntington National Bank now owns 2,355 shares of the company’s stock valued at $67,000 after buying an additional 1,618 shares during the period. Institutional investors and hedge funds own 8.37% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on FMS shares. Wall Street Zen upgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 28th. Bank of America lowered shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research note on Wednesday, October 15th. UBS Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research note on Wednesday, October 15th. Weiss Ratings upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Finally, Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, August 12th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Fresenius Medical Care AG & Co. KGaA presently has an average rating of “Reduce” and a consensus price target of $30.00.

Fresenius Medical Care AG & Co. KGaA Price Performance

NYSE FMS opened at $23.34 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.36 and a quick ratio of 1.00. The business has a 50 day simple moving average of $25.38 and a 200 day simple moving average of $26.19. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $22.05 and a 52-week high of $30.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.05. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.72% and a return on equity of 7.42%. The company had revenue of $5.73 billion during the quarter, compared to analysts’ expectations of $4.72 billion. As a group, analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.